Exploring the PD-1/PD-L1 pathway using Data, Tools, and Resources from RCSB.org @RCSBProteinDataBank
Exploring the PD-1/PD-L1 pathway using Data, Tools, and Resources from RCSB.org  @RCSBProteinDataBank
Uploaded February 2023 | Updated November 2026, 1 day ago
Based on case studies presented in doi.org/10.1002/pro.4482
00:00: Intro to PD-1/PD-L1
01:45: Exploring PDB ID 5jxe - Structure Summary page
04:35 How Pembrolizumab Disrupts PD-1:PD-L1 Binding
05:40 Compare structures
07:28 Other Therapeutic Anti-PD-1 Antibodies
Learn more about Pembrolizumab (pdb101.rcsb.org/motm/204) and other cancer therapy approaches on PDB-101 (pdb101.rcsb.org/).
Exploring the PD-1/PD-L1 pathway using Data, Tools, and Resources from RCSB.orgWhat is Cancer?Methods for Determining Atomic Structures: NMR Spectroscopy (from PDB-101)Closing Remarks | Celebrating PDB Contributions from Rutgers  |  Stephen K. BurleyDay 1 | Session 1 | Zihe Raop53 The Spell Checking MachinePDB50: Celebrating PDB Contributions from Rutgers | Helen M. BermanIntroduction | Using KBase to Access Protein Structures and ModelsUsing Mol* to Add Labels at RCSB.orgTarget Zero: CarmenPDB50 at the ACA: Day 1 | Erica Ollman Saphire, La Jolla Institute for ImmunologyPDB50 at the ACA: Day 1 | Panel Discussion
RCSBProteinDataBank |

Exploring the PD-1/PD-L1 pathway using Data, Tools, and Resources from RCSB.org

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER